This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Morin-Papunen, L. C. Articles by Martikainen, H. K. Search for Related Content PubMed PubMed Citation Articles by Morin-Papunen, L. C. Articles by Martikainen, H. K.

Decreased Serum Leptin Concentrations during Metformin Therapy in Obese Women with Polycystic Ovary Syndrome

Department of Obstetrics and Gynecology (L.M.-P., R.K., C.T., H.M.) and Department of Clinical Chemistry (A.R.), University Hospital of Oulu, 90220 Oulu, Finland

Address all correspondence and requests for reprints to: Morin-Papunen Laure, M.D., Department of Obstetrics and Gynecology, University Hospital of Oulu, Kajaanintie 50, 90220 Oulu, Finland.

Previous studies have suggested that metformin is clinically useful in the treatment of polycystic ovary syndrome (PCOS). The aim of this study was to evaluate whether the improvement of ovarian function achieved by metformin therapy is associated with changes in leptin concentrations. Twenty-six obese women with PCOS were treated with 500 mg metformin, x 3 daily, for 2 months; and 12 women continued the therapy for 4–6 months. A significant decrease in the serum leptin level was observed after 2 months of treatment in the whole study group (29.2 ± 12.7 ng/mL vs. 25.7 ± 10.9 ng/mL, P = 0.03). In the 12 women treated for 4–6 months, the mean serum leptin concentration decreased after 2 months (38.6 ± 9.3 ng/mL vs. 30.2 ± 8.1 ng/mL; P = 0.004) but slightly increased after 4–6 months of treatment (33.4 ± 15.7 ng/mL; not significant). These results indicate that insulin sensitizing therapy with metformin decreases the leptin concentrations in obese PCOS women.

This article has been cited by other articles:

				B. Schultes, K. M. Oltmanns, W. Kern, H. L. Fehm, J. Born, and A. Peters Modulation of Hunger by Plasma Glucose and Metformin J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1133 - 1141. [Abstract] [Full Text] [PDF]

				L. A. Stadtmauer, B. C. Wong, and S. Oehninger Should patients with polycystic ovary syndrome be treated with metformin?: Benefits of insulin sensitizing drugs in polycystic ovary syndrome--beyond ovulation induction Hum. Reprod., December 1, 2002; 17(12): 3016 - 3026. [Abstract] [Full Text] [PDF]

				H. Yarali, B. O. Yildiz, A. Demirol, H. B. Zeyneloglu, N. Yigit, O. Bukulmez, and Z. Koray Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial Hum. Reprod., February 1, 2002; 17(2): 289 - 294. [Abstract] [Full Text] [PDF]

				R. M. Koivunen, L. C. Morin-Papunen, A. Ruokonen, J. S. Tapanainen, and H. K. Martikainen Ovarian steroidogenic response to human chorionic gonadotrophin in obese women with polycystic ovary syndrome: effect of metformin Hum. Reprod., December 1, 2001; 16(12): 2546 - 2551. [Abstract] [Full Text] [PDF]

				M. Freemark and D. Bursey The Effects of Metformin on Body Mass Index and Glucose Tolerance in Obese Adolescents With Fasting Hyperinsulinemia and a Family History of Type 2 Diabetes Pediatrics, April 1, 2001; 107(4): e55 - e55. [Abstract] [Full Text] [PDF]

				R. Pasquali, A. Gambineri, D. Biscotti, V. Vicennati, L. Gagliardi, D. Colitta, S. Fiorini, G. E. Cognigni, M. Filicori, and A. M. Morselli-Labate Effect of Long-Term Treatment with Metformin Added to Hypocaloric Diet on Body Composition, Fat Distribution, and Androgen and Insulin Levels in Abdominally Obese Women with and without the Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., August 1, 2000; 85(8): 2767 - 2774. [Abstract] [Full Text]